Switch to:
Also traded in: Germany, Japan
» Details

Insider Trades

Latest Guru Trades with ESALF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:OTCPK:SGIOY, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, OTCPK:APNHF, NAS:MYL, OTCPK:HLUYY, OTCPK:IPSEY, NYSE:RDY, OTCPK:HKMPF, OTCPK:HYPMY, NYSE:VRX, NYSE:TARO, NYSE:PTHN, NAS:OPK, OTCPK:STDAF, NAS:NBIX, NAS:MDCO, NAS:ENDP, NAS:HZNP » details
Traded in other countries:EII.Germany, 4523.Japan,
Eisai Co Ltd is a healthcare company. It is engaged in providing prescription pharmaceuticals, consumer health care products, and diagnostics services.

Eisai Co Ltd was incorporated in Japan on December 6, 1941. It is a pharmaceutical company engaged in manufacturing and marketing of prescription medicines and over-the-counter products. The Company operates in five geographical segments including; Japan Pharmaceutical Business, Americas Pharmaceutical Business, Asia Pharmaceutical Business, EMEA Pharmaceutical Business, and Consumer Healthcare Business - Japan. The Japan Pharmaceutical Business is engaged in the sales of prescription drugs, generic drugs and diagnostics in Japan. The Americas Pharmaceutical Business is engaged in the development and marketing of Oncology-Related Products & Epilepsy Products. The Asia Pharmaceutical Business is engaged in selling Oncology-Related Products, Aricept, Pariet/AcipHex, and Epilepsy Products in Asia including China, South Korea, Taiwan, India and ASEAN nations. The EMEA Pharmaceutical Business sells Epilepsy Products, Oncology-Related Products, Aricept, & Pariet/AcipHex in Europe, the Middle East, Africa, Russia and Oceania. The Consumer Healthcare Business - Japan is engaged in the sale of Chocola BB group of products in Japan.

Ratios

vs
industry
vs
history
PE Ratio 31.66
ESALF's PE Ratio is ranked lower than
59% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.40 vs. ESALF: 31.66 )
Ranked among companies with meaningful PE Ratio only.
ESALF' s PE Ratio Range Over the Past 10 Years
Min: 12.4  Med: 24.75 Max: 119.42
Current: 31.66
12.4
119.42
PE Ratio without NRI 31.66
ESALF's PE Ratio without NRI is ranked lower than
58% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.84 vs. ESALF: 31.66 )
Ranked among companies with meaningful PE Ratio without NRI only.
ESALF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.4  Med: 24.75 Max: 119.43
Current: 31.66
12.4
119.43
Price-to-Owner-Earnings 26.51
ESALF's Price-to-Owner-Earnings is ranked higher than
59% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.72 vs. ESALF: 26.51 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ESALF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.36  Med: 18.41 Max: 32.62
Current: 26.51
10.36
32.62
PB Ratio 2.93
ESALF's PB Ratio is ranked higher than
51% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. ESALF: 2.93 )
Ranked among companies with meaningful PB Ratio only.
ESALF' s PB Ratio Range Over the Past 10 Years
Min: 1.83  Med: 2.32 Max: 4.2
Current: 2.93
1.83
4.2
PS Ratio 3.28
ESALF's PS Ratio is ranked lower than
52% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. ESALF: 3.28 )
Ranked among companies with meaningful PS Ratio only.
ESALF' s PS Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.94 Max: 6.6
Current: 3.28
0.96
6.6
Price-to-Free-Cash-Flow 27.82
ESALF's Price-to-Free-Cash-Flow is ranked lower than
58% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.72 vs. ESALF: 27.82 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ESALF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 19.89 Max: 206.63
Current: 27.82
5.75
206.63
Price-to-Operating-Cash-Flow 22.69
ESALF's Price-to-Operating-Cash-Flow is ranked lower than
63% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. ESALF: 22.69 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ESALF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.92  Med: 13.42 Max: 69.65
Current: 22.69
4.92
69.65
EV-to-EBIT 28.02
ESALF's EV-to-EBIT is ranked lower than
67% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.65 vs. ESALF: 28.02 )
Ranked among companies with meaningful EV-to-EBIT only.
ESALF' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.4  Med: 16.9 Max: 85.5
Current: 28.02
9.4
85.5
EV-to-EBITDA 19.69
ESALF's EV-to-EBITDA is ranked lower than
59% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. ESALF: 19.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
ESALF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 10.3 Max: 36.7
Current: 19.69
6.4
36.7
Shiller PE Ratio 32.11
ESALF's Shiller PE Ratio is ranked higher than
65% of the 158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 47.37 vs. ESALF: 32.11 )
Ranked among companies with meaningful Shiller PE Ratio only.
ESALF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 28.05  Med: 34.18 Max: 38.75
Current: 32.11
28.05
38.75
Current Ratio 2.83
ESALF's Current Ratio is ranked higher than
55% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. ESALF: 2.83 )
Ranked among companies with meaningful Current Ratio only.
ESALF' s Current Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.39 Max: 3.11
Current: 2.83
1.85
3.11
Quick Ratio 2.34
ESALF's Quick Ratio is ranked higher than
59% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. ESALF: 2.34 )
Ranked among companies with meaningful Quick Ratio only.
ESALF' s Quick Ratio Range Over the Past 10 Years
Min: 1.58  Med: 1.96 Max: 2.63
Current: 2.34
1.58
2.63
Days Inventory 143.58
ESALF's Days Inventory is ranked lower than
64% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. ESALF: 143.58 )
Ranked among companies with meaningful Days Inventory only.
ESALF' s Days Inventory Range Over the Past 10 Years
Min: 143.58  Med: 158.37 Max: 170.66
Current: 143.58
143.58
170.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.50
ESALF's Dividend Yield % is ranked higher than
68% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. ESALF: 2.50 )
Ranked among companies with meaningful Dividend Yield % only.
ESALF' s Dividend Yield % Range Over the Past 10 Years
Min: 1.7  Med: 4.04 Max: 6.71
Current: 2.5
1.7
6.71
Dividend Payout Ratio 0.78
ESALF's Dividend Payout Ratio is ranked lower than
82% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.36 vs. ESALF: 0.78 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ESALF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.48  Med: 0.84 Max: 1.12
Current: 0.78
0.48
1.12
Forward Dividend Yield % 2.81
ESALF's Forward Dividend Yield % is ranked higher than
70% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. ESALF: 2.81 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.50
ESALF's 5-Year Yield-on-Cost % is ranked higher than
57% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. ESALF: 2.50 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ESALF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.7  Med: 4.04 Max: 6.71
Current: 2.5
1.7
6.71
3-Year Average Share Buyback Ratio -0.10
ESALF's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. ESALF: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ESALF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2  Med: 0 Max: 1.3
Current: -0.1
-1.2
1.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 42.13
ESALF's Price-to-Net-Current-Asset-Value is ranked lower than
92% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ESALF: 42.13 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ESALF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 34.61  Med: 52.61 Max: 244.85
Current: 42.13
34.61
244.85
Price-to-Tangible-Book 5.77
ESALF's Price-to-Tangible-Book is ranked lower than
67% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. ESALF: 5.77 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ESALF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.21  Med: 6.25 Max: 19.26
Current: 5.77
4.21
19.26
Price-to-Intrinsic-Value-Projected-FCF 1.71
ESALF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
67% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. ESALF: 1.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ESALF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.05  Med: 1.2 Max: 2.13
Current: 1.71
1.05
2.13
Price-to-Median-PS-Value 1.69
ESALF's Price-to-Median-PS-Value is ranked lower than
77% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ESALF: 1.69 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ESALF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 1.02 Max: 2.93
Current: 1.69
0.52
2.93
Price-to-Graham-Number 2.85
ESALF's Price-to-Graham-Number is ranked lower than
61% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. ESALF: 2.85 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ESALF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.87  Med: 2.6 Max: 4.61
Current: 2.85
1.87
4.61
Earnings Yield (Greenblatt) % 3.54
ESALF's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ESALF: 3.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ESALF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 5.9 Max: 10.6
Current: 3.54
1.2
10.6
Forward Rate of Return (Yacktman) % -7.78
ESALF's Forward Rate of Return (Yacktman) % is ranked lower than
82% of the 358 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.67 vs. ESALF: -7.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ESALF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -13.6  Med: 0.7 Max: 22.4
Current: -7.78
-13.6
22.4

More Statistics

Revenue (TTM) (Mil) $4,883
EPS (TTM) $ 1.76
Beta-0.35
Short Percentage of Float0.00%
52-Week Range $53.50 - 66.25
Shares Outstanding (Mil)285.94
» More Articles for ESALF

Headlines

Articles On GuruFocus.com
Vanguard Adds to Eisai Stake Aug 17 2016 

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK